The Collagenase 3 pipeline drugs market research report outlays comprehensive information on the Collagenase 3 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Collagenase 3 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

The report also covers products from therapy areas such as Cardiovascular, Musculoskeletal Disorders, Central Nervous System, and Infectious Disease which include the indications Myocardial Infarction, Edema, Osteoarthritis, Arthritis, Osteoarthritis Pain, Arthralgia (Joint Pain), Chikungunya Fever, and Alphavirus Infections. It also reviews key players involved in Collagenase 3 targeted therapeutics development with respective active and dormant or discontinued products.

The Collagenase 3 pipeline targets constitutes close to eight molecules. Out of which, approximately six molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Preclinical, and Discovery stages are 1, 4, and 1 respectively. Similarly, the universities portfolio in Preclinical comprises 2 molecule.

Collagenase 3 overview

Collagenase-3 (MMP13) is a member of the matrix metalloproteinase (MMP) family of neutral endopeptidases. It plays a role in the degradation of extracellular matrix proteins including fibrillar collagen, fibronectin, TNC and ACAN, wound healing, tissue remodeling, cartilage degradation, bone development, bone mineralization and ossification.

For a complete picture of Collagenase 3’s drug pipeline, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.